Moderna is also developing a single vaccine that combines a booster dose against Covid-19 with its experimental flu shot
Moderna’s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators in about March, CEO Stephane Bancel said on Monday.
“Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don’t want to get two to three shots a winter.” Earlier in January, Moderna’s CEO said people may need a fourth shot in the northern hemisphere’s autumn of 2022 as the efficacy of boosters against Covid-19 was likely to decline over the next few months.
Speaking at the same event, top US infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.